Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 470983, 10 pages
Review Article

Adult Stem Cell as New Advanced Therapy for Experimental Neuropathic Pain Treatment

1Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi Milano, 20129 Milano, Italy
2I.R.C.C.S. Istituto Ortopedico Galeazzi, 20161 Milano, Italy
3Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, 20129 Milano, Italy
4Dipartimento di Biotecnologie e Bioscienze, Università Milano Bicocca, 20126 Milano, Italy
5Istituto di Ricovero e Cura a Carattere Scientifico Opera di San Pio da Pietralcina, 71013 San Giovanni Rotondo, Italy

Received 12 June 2014; Accepted 23 July 2014; Published 13 August 2014

Academic Editor: Livio Luongo

Copyright © 2014 Silvia Franchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Neuropathic pain (NP) is a highly invalidating disease resulting as consequence of a lesion or disease affecting the somatosensory system. All the pharmacological treatments today in use give a long lasting pain relief only in a limited percentage of patients before pain reappears making NP an incurable disease. New approaches are therefore needed and research is testing stem cell usage. Several papers have been written on experimental neuropathic pain treatment using stem cells of different origin and species to treat experimental NP. The original idea was based on the capacity of stem cell to offer a totipotent cellular source for replacing injured neural cells and for delivering trophic factors to lesion site; soon the researchers agreed that the capacity of stem cells to contrast NP was not dependent upon their regenerative effect but was mostly linked to a bidirectional interaction between the stem cell and damaged microenvironment resident cells. In this paper we review the preclinical studies produced in the last years assessing the effects induced by several stem cells in different models of neuropathic pain. The overall positive results obtained on pain remission by using stem cells that are safe, of easy isolation, and which may allow an autologous transplant in patients may be encouraging for moving from bench to bedside, although there are several issues that still need to be solved.